MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)
NCT ID: NCT00449956
Last Updated: 2017-06-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
474 participants
INTERVENTIONAL
2007-03-12
2008-02-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)
NCT00108017
Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
NCT01284166
Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide
NCT01062971
A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)
NCT00546286
Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT00822055
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
combination of dorzolamide hydrochloride and timolol maleate
dorzolamide hydrochloride (+) timolol maleate
Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
2
Concomitant use of dorzolamide hydrochloride and timolol maleate
Comparator: timolol maleate
timolol maleate 0.5%, 8-week
Comparator: dorzolamide hydrochloride
dorzolamide hydrochloride 1%, 8-week
3
timolol maleate
Comparator: timolol maleate
timolol maleate 0.5%, 8-week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dorzolamide hydrochloride (+) timolol maleate
Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
Comparator: timolol maleate
timolol maleate 0.5%, 8-week
Comparator: dorzolamide hydrochloride
dorzolamide hydrochloride 1%, 8-week
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Administration contradiction to timolol and dorzolamide
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
References
Explore related publications, articles, or registry entries linked to this study.
Kitazawa Y, Araie M; Research Group on MK-0507A. [Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension]. Nippon Ganka Gakkai Zasshi. 2011 Jun;115(6):495-507. Japanese.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK0507A-149
Identifier Type: -
Identifier Source: secondary_id
2007_011
Identifier Type: -
Identifier Source: secondary_id
0507A-149
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.